Sirtris Pharmaceuticals To Present at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007
Posted on: Thursday, 12 July 2007, 09:19 CDT
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that it will be presenting at the 6th Annual Metabolic Diseases Drug Discovery and Development World Summit in San Diego, California. Jill Milne, Ph.D., Senior Director of Biology at Sirtris, will deliver a keynote address "SIRT1 Activation: A Novel Mechanism for Treating Type 2 Diabetes." Her presentation is scheduled to be delivered at 8:45 am PST on Tuesday, July 17, 2007.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company's headquarters are in Cambridge, Massachusetts.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Sirtris Pharmaceuticals, its product candidates, and those candidates' clinical potential. These forward-looking statements about future expectations, plans and prospects of Sirtris Pharmaceuticals involve significant risks, uncertainties and assumptions, including risks related to the lack of results that would provide a basis for predicting whether any of the Company's product candidates will be safe or effective, or receive regulatory approval, the Company's potential inability to initiate and complete preclinical studies and clinical trials for its product candidates, the fact that none of the Company's product candidates has received regulatory approvals, the potential inability of the Company to gain market acceptance of the Company's product candidates, and those other risks factors that can be found in the Company's filings with the Securities and Exchange Commission. Actual results may differ materially from those Sirtris Pharmaceuticals contemplated by these forward-looking statements. Sirtris Pharmaceuticals does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.
Source: Business Wire
Related Articles
- Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
- China Biopharma Reaches Agreement With a Regional Pharma to Launch New Pharmaceutical Products
- Research and Markets: Examine the Performance, Products, Pipeline and Potential of Merck & Co
- Gadolinium-Based MRI Contrast Agents Linked to Potentially Fatal Disease Known As Nephrogenic Systemic Fibrosis (NSF). Informational Website and Claims Filing Department Opened By Law Firm to Assist NSF Patients Nationwide
- Back on Job, Snow Looks Forward to Busy Schedule
- Timothy R. Wright Appointed President of Tyco Healthcare's Pharmaceutical Products and Imaging Solutions Units
- Heinz Announces Preliminary Proxy Voting Results; Looks Forward With Confidence to Executing Its Plans to Increase Shareholder Value
- New Report on Nanotechnology in Agriculture and Food Looks at Potential Applications, Benefits and Risks
- We Should All Look Forward to a Productive New School Year
- Macugen(R) (Pegaptanib Sodium Injection) Named Innovative Pharmaceutical Product Of The Year At The 2005 Pharmaceutical Achievement Awards
 |
 |
User Comments (0)
RSS Feeds